Sectors
REPL
Replimune Group, Inc.
15.33
3 x 10.95
1 x 15.34
bid
ask
-
0.17
1.09%
02:07 PM
timesize
| Ytd | 57.72% | |
| 1y | 183.90% |
14.92
day range
15.51
1.50
52 week range
16.15
| Open | 15.36 | Prev Close | 15.50 | Low | 14.92 | High | 15.51 | Mkt Cap | 1.44B |
| Vol | 626.42K | Avg Vol | 4.98M | EPS | -3.15 | P/E | N/A | Forward P/E | -7.61 |
| Beta | 0.88 | Short Ratio | 3.43 | Inst. Own | 104.19% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 11.81 | 200-d Avg | 8.43 | 1yr Est | 19.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-05 | 2026-09 | -0.75 | N/A | N/A | N/A |
| 2026-08-14 | 2026-06 | -0.69 | -0.72 | -0.03 | -3.75% |
| 2026-06-29 | 2026-03 | -0.73 | -0.76 | -0.03 | -4.11% |
| 2026-02-03 | 2025-12 | -0.77 | -0.77 | N/A | -0.22% |
| 2025-11-06 | 2025-09 | -0.87 | -0.9 | -0.03 | -3.45% |
| 2025-08-07 | 2025-06 | -0.83 | -0.95 | -0.12 | -14.46% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-07 | JP Morgan | Upgrade | Overweight | Overweight |
| 2026-08-07 | Wedbush | Upgrade | Neutral | Outperform |
| 2026-08-04 | Leerink Partners | Upgrade | Market Perform | Outperform |
| 2026-07-31 | Wedbush | Upgrade | Neutral | Neutral |
| 2026-07-31 | Cantor Fitzgerald | Upgrade | Neutral | Overweight |
| 2026-06-30 | Wedbush | Upgrade | Neutral | Neutral |
Profile
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-08-19 | ASTLEY-SPARKE PHILIP | Director | 1.36M | Stock Gift |
| 2025-12-08 | DHINGRA KAPIL | Director | 0.00 | Sale |
| 2026-08-16 | HILL EMILY LUISA | Chief Financial Officer | 215.85K | Sale |
| 2026-08-09 | PATEL SUSHIL | Chief Executive Officer | 708.15K | Sale |
| 2026-05-31 | SARCHI CHRISTOPHER | Officer | 180.96K | Sale |
| 2026-08-09 | SCHWENDENMAN ANDREW | Officer | 99.43K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Baker Bros. Advisors, LP | 11.05M | 171.20M | 11.78% |
| 2026-06-29 | Blackrock Inc. | 8.96M | 138.86M | 9.55% |
| 2026-06-29 | RTW Investments LP | 7.41M | 114.88M | 7.90% |
| 2026-06-29 | Ridgeback Capital Investments L.P. | 7.31M | 113.32M | 7.79% |
| 2026-06-29 | Goldman Sachs Group Inc | 4.54M | 70.39M | 4.84% |
| 2026-06-29 | State Street Corporation | 4.44M | 68.82M | 4.73% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.74M | 42.54M | 2.93% |
| 2026-03-30 | T. Rowe Price New Horizons Fund, Inc. | 2.41M | 37.41M | 2.57% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 2.07M | 32.13M | 2.21% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.85M | 28.65M | 1.97% |
| 2026-03-30 | T. Rowe Price Health Sciences Fund, Inc. | 1.43M | 22.13M | 1.52% |
| 2026-06-29 | Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.24M | 19.15M | 1.32% |